Evidence map›Paper›PMID 39776249›Full record

SynthesisAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Gil D Rabinovici, David S Knopman, Javier Arbizu, Tammie L S Benzinger, Kevin J Donohoe, Oskar Hansson, Peter Herscovitch, Phillip H Kuo, Jennifer H Lingler, Satoshi Minoshima and 6 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  6. Trial
  7. Quantitative agreement between AMYclz and CortexID forJapanese journal of radiology · 2026
    Article
  8. Annals of nuclear medicine · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Exploring longitudinal relationships among Alzheimer's disease biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  15. Review
  16. The clinical Alzheimer's disease spectrum classified in the A/T/N framework withEuropean journal of nuclear medicine and molecular imaging · 2026
    Observational
  17. Review
  18. Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  19. Classification of tau status with machine learning models in amyloid-positive cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Gil D RabinoviciDepartment of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-3626-4265
David S KnopmanMayo Clinic Neurology and Neurosurgery, Rochester, Minnesota, USA.
Javier ArbizuDepartment of Nuclear Medicine, University of Navarra Clinic, Pamplona, Spain.
Tammie L S BenzingerMallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Kevin J DonohoeNuclear Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Oskar HanssonDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Peter HerscovitchPositron Emission Tomography Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Phillip H KuoMedical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Arizona, USA.
Jennifer H LinglerDepartment of Health and Community Systems, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Satoshi MinoshimaDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Julie C PriceDepartment of Radiology, Massachusetts General Hospital, Boston, Charlestown, Massachusetts, USA.
Stephen P SallowayDepartment of Neurology and Psychiatry the Warren Alpert School of Medicine at Brown University, Providence, Rhode Island, USA.
Christopher J WeberAlzheimer's Association, Chicago, Illinois, USA.
Maria C CarrilloCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Keith A JohnsonCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.

methodsThe workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as "rarely appropriate," "uncertain," or "appropriate." Ratings were performed separately for amyloid and tau PET as stand-alone modalities.

resultsFor amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. HIGHLIGHTS: A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.

Indexed as

Alzheimer DiseaseAmyloidBrainMolecular ImagingPositron-Emission Tomographytau ProteinsHumansNuclear MedicineSocieties, MedicalAmyloidtau ProteinsAlzheimer's diseaseamyloid PETappropriate use criteriabiomarkersbrain pathologyclinical carecognitive impairmentdementiadiagnosisearly detectionmemory disordersmolecular imagingneuroimagingneurologyPET imagingpositron emission tomographytau PETtherapeutic strategiestreatment

Identifiers

PMID39776249
PMCPMC11772739

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.